➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Colorcon
McKinsey
Mallinckrodt
AstraZeneca

Last Updated: October 21, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ELIXOPHYLLIN

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for ELIXOPHYLLIN

Trial ID Title Status Sponsor Phase Start Date Summary
NCT04551170 ↗ Theophylline Treatment for Pseudohypoparathyroidism - Children 2-12 Years Old Recruiting Vanderbilt University Medical Center Phase 2 2020-07-13 Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature and resistance to multiple hormones. This phase 2 clinical trial and open-label extension study will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, slow the rate of growth plate closure and decrease hormone resistance in children.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for ELIXOPHYLLIN

Condition Name

Condition Name for ELIXOPHYLLIN
Intervention Trials
Pseudohypoparathyroidism Type 1a 1
Pseudohypoparathyroidism 1
Albright Hereditary Osteodystrophy 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for ELIXOPHYLLIN
Intervention Trials
Pseudopseudohypoparathyroidism 1
Pseudohypoparathyroidism 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for ELIXOPHYLLIN

Trials by Country

Trials by Country for ELIXOPHYLLIN
Location Trials
United States 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for ELIXOPHYLLIN
Location Trials
Tennessee 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for ELIXOPHYLLIN

Clinical Trial Phase

Clinical Trial Phase for ELIXOPHYLLIN
Clinical Trial Phase Trials
Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for ELIXOPHYLLIN
Clinical Trial Phase Trials
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for ELIXOPHYLLIN

Sponsor Name

Sponsor Name for ELIXOPHYLLIN
Sponsor Trials
Vanderbilt University Medical Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for ELIXOPHYLLIN
Sponsor Trials
Other 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
McKesson
Moodys
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.